PNC Financial Services Group’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-400
Closed -$39K – 4198
2019
Q3
$39K Hold
400
– – ﹤0.01% 3050
2019
Q2
$41K Hold
400
– – ﹤0.01% 3041
2019
Q1
$46K Sell
400
-350
-47% -$25.7K ﹤0.01% 2992
2018
Q4
$29K Sell
750
-2,175
-74% -$94.3K ﹤0.01% 3152
2018
Q3
$160K Buy
2,925
+325
+13% +$22.2K ﹤0.01% 2310
2018
Q2
$215K Buy
2,600
+500
+24% +$38.6K ﹤0.01% 2141
2018
Q1
$140K Buy
2,100
+1,000
+91% +$57.7K ﹤0.01% 2373
2017
Q4
$57K Buy
1,100
+400
+57% +$28.7K ﹤0.01% 2885
2017
Q3
$62K Hold
700
– – ﹤0.01% 2812
2017
Q2
$42K Hold
700
– – ﹤0.01% 3000
2017
Q1
$37K Hold
700
– – ﹤0.01% 3030
2016
Q4
$35K Sell
700
-150
-18% -$8.04K ﹤0.01% 3000
2016
Q3
$52K Buy
850
+96
+13% +$5.53K ﹤0.01% 2803
2016
Q2
$39K Buy
754
+4
+0.5% +$171 ﹤0.01% 2947
2016
Q1
$22K Hold
750
– – ﹤0.01% 3249
2015
Q4
$34K Sell
750
-50
-6% -$2.62K ﹤0.01% 3029
2015
Q3
$33K Buy
800
+50
+7% +$2.61K ﹤0.01% 3122
2015
Q2
$45K Buy
750
+50
+7% +$3.31K ﹤0.01% 3080
2015
Q1
$54K Buy
+700
New +$40.3K ﹤0.01% 3012

PNC Financial Services Group's ONCE Position: Q4 2019 in Review

PNC Financial Services Group sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 400 shares — an estimated $39K sold.

PNC Financial Services Group first reported a position in ONCE in Q1 2015 and held it in 19 quarters. The position peaked at $215K in Q2 2018. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

  • PNC Financial Services Group reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • PNC Financial Services Group sold 400 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $39K.
  • PNC Financial Services Group first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 19 quarters.
  • PNC Financial Services Group's Spark Therapeutics, Inc. Common Stock position peaked at $215K in Q2 2018.
  • 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on PNC Financial Services Group's 13F filing for Q4 2019, filed 7 Feb 2020.